Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians
ConclusionsUS payers and physicians who have experience with biosimilars have favorable views of oncology biosimilars, particularly for treatment-na ïve patients. A framework for integrating biosimilars into oncology practice is developing, primarily driven by insurance coverage, contracting, and cost benefits.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Drugs & Pharmacology | Hematology | Insurance | Managed Care | Practice Management